Cefoxitin continuous infusion for lung infection caused by the mycobacterium abscessus group

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3570-3571

  Czaja, Christopher A ^a   Levin, Adrah ^a   Moridani, Majid ^b   Krank, Jessica L ^a   Curran Everett, Douglas ^a,c   Anderson, Peter L ^d  

^a DEPARTMENT OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Food Science and Human Nutrition   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; ANTIINFECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CASE REPORT; CONTINUOUS INFUSION; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STEADY STATE; ATYPICAL MYCOBACTERIUM; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; FIBROSIS; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASES; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS;

AGED; ANTI-BACTERIAL AGENTS; CEFOXITIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG DISEASES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84901262361     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02763-14     Document Type: Letter

References (10)

1. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, de Oca RM, Shea YR, Seitz AE, Holland SM, Olivier KN. 2010. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am. J. Resp. Crit. Care Med. 182:970-976. http://dx.doi.org/10.1164/ rccm.201002-0310OC.
2. Jeon K, Kwon OJ, Lee NY, Kim B, Kook Y, Lee S, Park YK, Kim CK, Koh W. 2009. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am. J. Resp. Crit. Care Med. 180:896-902. http://dx.doi.org/10.1164/rccm.200905-0704OC.
3. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CD. 2011. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin. Infect. Dis. 52:565-571. http://dx.doi.org/10.1093/cid/ciq237.
4. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. 2005. Continuous versus intermittent administration of antibiotics: a meta-Analysis of randomized controlled trials. Lancet Infect. Dis. 5:581-589. http://dx.doi.org/10.1016/S1473-3099(05)70218-8.
5. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. 2009. A systematic review of clinical benefits of continuous infusion of-lactam antibiotics. Crit. Care Med. 37:2071-2078. http://dx.doi.org/10.1097/CCM.0b013e31 81a0054d.
6. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Lademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am. J. Resp. Crit. Care Med. 175: 367-416. http://dx.doi.org/10.1164/rccm. 200604-571ST.
7. CLSI. 2011. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard-second edition. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Merck & Co. Inc. 2003. Mefoxin® (cefoxitin for infusion). Package insert. http://www.fda.gov/ohrms/dockets/dailys/03/Jun03/060403/03p-0227- cp00001-03-exhibit-b-vol1.pdf. Accessed 15 February 2014.
9. Ko H, Cathcart KS, Griffith DL, Peter GR, Adams WJ. 1989. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob. Agents Chemother. 33:356-361. http://dx.doi.org/10.1128/AAC.33.3.356.
10. Rowland M, Tozer TN. 2011. Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.